Shares of Equillium, Inc. (EQ) are gaining more than 14 percent or $0.86 in Friday's morning trade at $6.86.
Thursday, Equillium said it has received FDA clearance to commence a phase III clinical trial of Itolizumab in hospitalized COVID-19 patients suffering from acute respiratory distress syndrome or ARDS. The company plans to begin patient enrollment in the trial named EQUINOX in the fourth quarter, with initial clinical data expected mid-year 2021.
Equillium has traded in a range of $2.20 to $27.05 in the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
December 19, 2025 15:10 ET U.S. inflation data and interest rate decisions by major central banks were the highlights of this busy week for economics news flow. Employment data and survey results on the housing markets also gained attention in the U.S. In Europe, the European Central Bank and Bank of England announced their policy decisions and macroeconomic projections.